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ORIGINAL ARTICLE
Certolizumab Pegol Efficacy Across Methotrexate
Regimens: A Pre-Specified Analysis of Two
Phase III Trials
BERNARD COMBE,1 DANIEL E. FURST,2 EDWARD C. KEYSTONE,3 DESIREE VAN DER HEIJDE,4
KRISTEL LUIJTENS,5 LUCIAN IONESCU,5 NITI GOEL,6 AND PAUL EMERY7
Objective. Anti–tumor necrosis factor (anti-TNF) agents are frequently used in combination with methotrexate (MTX)
to treat rheumatoid arthritis (RA). We investigated the effect of a background MTX dose, in combination with anti-
TNF certolizumab pegol (CZP), on treatment efficacy and safety in RA patients.
Methods. A pre-specified subgroup analysis comparing 2 MTX dosage categories (<15 mg/week and ‡15 mg/week)
was carried out using data pooled from phase III clinical trials, Rheumatoid Arthritis Prevention of Structural Dam-
age 1 (RAPID 1) and RAPID 2, according to treatment group: CZP 200 mg, CZP 400 mg, or placebo, every 2 weeks.
Inclusion criteria required MTX dosage ‡10 mg/week. Efficacy end points included week 24 American College of
Rheumatology criteria for 20%, 50%, and 70% improvement (ACR20/50/70) responses analyzed by logistic regression,
and changes from baseline in the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-
ESR) and the modified Sharp/van der Heijde score (SHS) were analyzed by analysis of covariance. Incidence rates of
treatment-emergent adverse events (TEAEs) were categorized by baseline MTX dose. Post hoc sensitivity analysis
investigated 3 MTX dose categories: £10 mg/week, >10 and £15 mg/week, and >15 mg/week.
Results. A total of 638, 635, and 325 patients received CZP 200 mg, CZP 400 mg, and placebo, respectively. At week
24, treatment responses in both CZP groups were uninfluenced by baseline MTX dose category, and were superior to
the placebo group for all investigated end points: ACR20/50/70, DAS28-ESR, and SHS. TEAE incidence rates were
higher in patients receiving MTX ‡15 mg/week for most TEAE types across treatment groups.
Conclusion. CZP efficacy was not affected by background MTX dose category. It can be hypothesized that to minimize
TEAEs, background MTX doses could be tailored to individual patient tolerance without affecting CZP efficacy.
INTRODUCTION
Methotrexate (MTX), the most commonly used synthetic
disease-modifying antirheumatic drug (DMARD) (1–3),
was introduced for the treatment of rheumatoid arthritis
(RA) more than 30 years ago. It is generally administered
once weekly at dosages ranging from 7.5 to 30 mg/week
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(3,4). MTX has one of the best benefit to risk ratios of any
DMARD used in the management of RA (3,5). However,
some RA patients are intolerant to MTX. Moreover, many
patients fail to respond completely so the dose needs to be
increased or MTX is combined with other DMARDs. Fur-
thermore, dose escalation may be necessary over time in
some patients treated with MTX because of loss of
response (6), which increases the risk of related adverse
events (AEs). Most AEs associated with MTX, notably gas-
trointestinal (GI) AEs, are dose dependent (4,6–9). Patients
receiving high doses may eventually require reduction to
potentially less effective MTX doses or discontinuation of
therapy because of AEs.
Combining DMARDs is a widely used therapeutic
approach to improve RA disease control (10–14). Tumor
necrosis factor (TNF) plays a central role in the pathogene-
sis of RA (15), and anti-TNFs have demonstrated efficacy
in reducing the signs and symptoms of RA, as well as
inhibiting structural damage, especially when used in
combination with MTX (10–14,16). Indeed, the combina-
tion of an anti-TNF and MTX is more effective than mono-
therapy with either an anti-TNF or MTX (17,18).
Certolizumab pegol (CZP) is a PEGylated anti-TNF con-
sisting of a Fab0 fragment attached to a 40 kDa polyethyl-
ene glycol (PEG) moiety. In 2 phase III, placebo-controlled
clinical trials (Rheumatoid Arthritis Prevention of Struc-
tural Damage [RAPID]1 and 2), CZP significantly reduced
the signs and symptoms of active RA and inhibited pro-
gression of structural joint damage when administered as
add-on therapy to MTX in patients with an inadequate
response to MTX therapy alone (19,20).
Because dose-response and dose-toxicity relationships
exist for MTX therapy in RA and the optimal MTX dose is
determined on an individual basis (4,6–9), it is important to
establish whether an anti-TNF agent will be effective across
a wide dose range of background MTX doses. The objective
of this subgroup analysis of data from the RAPID 1 and 2
trials was to assess the efficacy and safety/tolerability of CZP
compared to placebo in RA patients receiving different
background MTX doses.
MATERIALS AND METHODS
Study design. RAPID 1 (NCT00152386) and RAPID 2
(NCT00160602) study designs have been described previ-
ously (19,20). Briefly, RAPID 1 and 2 were phase III, ran-
domized, double-blind placebo-controlled trials, with
durations of 52 weeks (RAPID 1) and 24 weeks (RAPID 2),
respectively. Patients were eligible for inclusion in the tri-
als if they met the following criteria: age $18 years with a
diagnosis of RA, defined by American College of Rheuma-
tology (ACR) 1987 criteria (21), of $6 months but ,15
years’ duration; had received MTX ($10 mg/week) for $6
months, with a stable dose for $2 months prior to baseline
and had active RA at screening and baseline, defined as$9
tender joints and$9 swollen joints; and had an erythrocyte
sedimentation rate (ESR; Westergren) $30 mm/hour or a
C-reactive protein concentration.15 mg/liter.
Patients were randomized 2:2:1 to 1 of 2 CZP treatment
regimens (400 mg loading dose at weeks 0, 2, and 4, fol-
lowed by 200 mg or 400 mg every 2 weeks) or placebo,
added to stable-dose MTX. All patients continued MTX
therapy at the same dose as at study entry ($10 mg/week).
Patients failing to achieve ACR criteria for 20% improve-
ment (ACR20) response at both weeks 12 and 14 were with-
drawn from the study at week 16 (as per study protocol).
The primary efficacy end points were an ACR20 response
rate at week 24 (RAPID 1 and RAPID 2) and change from
baseline in the modified Sharp/van der Heijde score (SHS)
at week 52 (RAPID 1) (19,20). Sample size was determined
based on expected differences between the CZP groups and
placebo for both primary efficacy end points.
Analysis by baseline MTX dose. A pre-specified sub-
group analysis of the primary end point (i.e., ACR20
response at week 24) was performed in both RAPID 1 and
2 to assess the efficacy of CZP according to MTX dose cate-
gory at enrollment (,15 mg/week or$15 mg/week).
Subsequently, a further subgroup analysis pooled data
from RAPID 1 and 2 studies by treatment group (CZP
200 mg, CZP 400 mg, or placebo) and excluded all patients
with unknown MTX dose at baseline. Efficacy and safety/
tolerability were assessed in each pooled treatment group
according to baseline MTX dose category: ,15 mg/week
or $15 mg/week. A post hoc sensitivity analysis was also
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undertaken in which patients were subdivided into 3
MTX dose categories as follows: #10 mg/week, .10 and
#15 mg/week, and.15 mg/week.
Efficacy analyses. The efficacy end points examined in
the intent-to-treat (ITT) population were week 24 ACR20/
50/70 response rates, change from baseline in the Disease
Activity Score in 28 joints using the ESR (DAS28-ESR)
assessment, DAS28-ESR remission (defined as DAS28-ESR
,2.6), DAS28-ESR low disease activity (LDA; defined as
DAS28-ESR#3.2), and change from baseline in the SHS.
Safety analyses. Safety/tolerability end points includ-
ed treatment-emergent adverse events (TEAEs), which
were defined as AEs occurring after the first administra-
tion of the study drug and up to 12 weeks after the last
dose for patients not continuing into the open-label exten-
sion study. TEAEs were classified by system organ class
and preferred term, according to the Medical Dictionary
for Regulatory Activities (MedDRA), version 9.0. Tubercu-
losis (TB) was classified according to the MedDRA high-
level term, which included both latent TB and active TB.
Analysis of TEAEs (incidence rate per 100 patient-
years6 95% confidence intervals) was conducted by base-
line MTX dose category in the safety population, defined
as any patient who received at least 1 dose of study drug.
Due to a lack of TEAEs occurring in $10% of patients,
“most frequent” TEAEs were defined as those occurring in
$5% of patients in any one treatment group.
Statistical analysis. To explore differences in the CZP
treatment effect compared to placebo between the 2 or 3
MTX dose categories, a factor for MTX category and an
interaction term between MTX category and treatment
were added to the logistic regression models, which origi-
nally had treatment and geographic region as factors, pre-
viously used to assess treatment effect on responder rates
in the RAPID 1 and RAPID 2 trials (19,20). For change
from baseline in SHS and DAS28-ESR scores, an analysis
of covariance model, with treatment and region as factors,
and baseline as covariate, was utilized (19,20). All reported
P values can only be interpreted in an exploratory manner,
i.e., are nominal.
Following withdrawal or the use of rescue medication,
missing patient data were imputed using nonresponder
imputation for ACR20/50/70 responses and DAS28-ESR
remission and LDA, linear extrapolation for SHS, and last
observation carried forward for the DAS28-ESR change from
baseline. Missing SHS baseline values were imputed by the
median value of all patients within the treatment group.
RESULTS
Patients. Of the 1,601 patients originally randomized into
RAPID 1 and RAPID 2, the MTX dose was available for
1,598 (638, 635, and 325 patients in the 200 mg CZP plus
MTX, 400 mg CZP plus MTX, and placebo plus MTX
groups, respectively) and were included in these analyses.
Baseline demographics and disease activity were similar
across the 3 treatment groups (CZP 200 mg, CZP 400 mg, or
placebo) regardless of baseline MTX dose category (data not
shown). Overall, more than 90% of patients were of Cauca-
sian descent. Three patients were receiving MTX under
10 mg/week at study baseline (study protocol deviators),
and 792 patients received MTX at a dosage of 10 mg/week
(see Table 1 and Supplementary Table 1, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22676/abstract. One patient ran-
domized to the CZP 200 mg group did not receive treatment,
and 2 patients randomized to the placebo group received
CZP 200 mg [and were therefore included in the placebo
group for ITT analyses and in the CZP 200 mg group for
safety analyses]). Overall, 963 patients (60.3%) received
MTX dosages of ,15 mg/week and 635 (39.7%) received
dosages of$15 mg/week.
In the sensitivity analysis (MTX 3-dose categorization),
baseline demographics and disease activity were also
found to be similar across the treatment groups regardless
of baseline MTX dose category (data not shown).
Clinical efficacy. In the MTX 2-dose categorization (pre-
specified analysis), ACR20 response rates at week 24 were
greater in patients receiving CZP 200 mg or 400 mg than in
patients receiving placebo (P , 0.001 by logistic regres-
sion), and this effect was similar regardless of baseline
MTX dose category (MTX ,15 mg/week: 60.1%, 60.2%,
and 9.8%; MTX $15 mg/week: 55.6%, 58.7%, and 15.1%)
(Figure 1A). The baseline MTX dose category did not seem
to have an impact on the treatment effect (Figure 1A).
ACR20 response rates at week 24 in the MTX 3-dose cate-
gorization sensitivity analysis (#10 mg/week, .10 and
#15 mg/week, and .15 mg/week) were also greater in pa-
tients receiving CZP 200 mg or CZP 400 mg than in patients
receiving placebo (Table 1). Response rates in the CZP groups
appeared unaffected by baseline MTX dose category, ranging
from 53.6% to 59.9% across the 3 MTX dose categories at
week 24 in the CZP 200 mg group. Similar results were
observed for patients in the CZP 400 mg group. In contrast,
in patients receiving placebo, ACR20 response rates were
higher in those receiving MTX.15 mg/week compared with
those receiving MTX #10 or .10 to #15 mg/week at week
24 (21.4% versus 10.2% and 10.4%, respectively) (Table 1).
ACR50 and ACR70 responses at week 24 were greater in
patients receiving CZP 200 mg or CZP 400 mg than in
patients receiving placebo (Figure 1B and C). Numerically,
slightly higher ACR50 and ACR70 response rates were
observed in the higher MTX dose category ($15 mg/week)
compared with the lower MTX category (,15 mg/week)
across all treatment groups (Figure 1B and C).
In the MTX 3-dose categorization, ACR50 and ACR70
response rates at week 24 in all 3 MTX dose categories
were greater in patients receiving CZP 200 mg or 400 mg
than in patients receiving placebo, and response rates were
only slightly higher in those receiving MTX .15 mg/week
and .10 and #15 compared with those receiving MTX
#10 mg/week (Table 1).
The mean change from baseline in DAS28-ESR at week
24 was greater in patients receiving CZP 200 mg or CZP
400 mg than in patients receiving placebo (Figure 2)
(19,20). Although a numerically greater mean change was
observed in the higher dose category for the CZP 200 mg
group (Figure 2B), similar treatment effects were seen
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across baseline MTX dose categories in the placebo and
CZP 400 mg groups. DAS28-ESR remission rates at week
24 were also higher in patients receiving CZP 200 mg
and CZP 400 mg compared to patients receiving placebo
(MTX ,15 mg/week: 7.6%, 9.8%, and 1.0%; MTX
$15 mg/week: 15.6%, 13.4%, and 1.8%) (see Supplemen-
tary Figure 1A, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.22676/abstract). Patients receiving CZP 200 mg or CZP
400 mg were more likely to report LDA at week 24 com-
pared to placebo patients (MTX ,15 mg/week: 15.1%,
19.8%, and 1.5%; MTX $15 mg/week: 27.2%, 24.4%, and
4.4%) with treatment effect being similar across baseline
MTX dose categories (Supplementary Figure 1B, available
at http://onlinelibrary.wiley.com/doi/10.1002/acr.22676/
abstract). In the MTX 3-dose categorization, treatment
effect appeared unaffected by baseline MTX dose category
for change from baseline in DAS28-ESR, DAS28-ESR
remission, and LDA (Table 1).
Inhibition of progression of structural damage. Mean
change from baseline in SHS at week 24 was lower in
patients receiving CZP 200 mg or CZP 400 mg versus those
receiving placebo, regardless of baseline MTX dose catego-
ry (,15 mg/week and $15 mg/week) (Figure 3). Baseline
MTX dose category did not seem to have an impact upon
treatment effect (Figure 3). In patients receiving placebo,
mean changes from baseline in SHS at week 24 were
similar in those receiving MTX ,15 mg/week and
$15 mg/week (1.2 versus 1.4). Mean changes in erosion
Figure 1. American College of Rheumatology criteria for 20%
(A), 50% (B), and 70% (C) improvement (ACR20/50/70)
response rates at week 24 by baseline methotrexate (MTX) dose
category (intent-to-treat population; MTX 2-dose categorization).
Interaction P value between MTX ,15 mg/week and MTX
$15 mg/week across treatment groups based on logistic regres-
sion. Individual group P values based on logistic regression
without interaction factor. CZP5 certolizumab pegol.
Figure 2. Mean change from baseline in the Disease Activity
Score in 28 joints using the erythrocyte sedimentation rate
(DAS28[ESR]) over time by baseline methotrexate (MTX) dose
category (intent-to-treat population; MTX 2-dose categorization).
A, placebo plus MTX, B, certolizumab pegol (CZP) 200 mg plus
MTX, and C, CZP 400 mg plus MTX. Week 24 interaction P val-
ue5 0.119 (MTX ,15 mg/week vs. MTX $15 mg/week across
treatment groups, based on analysis of covariance).
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(see Supplementary Figure 2A, available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22676/abstract) and joint space nar-
rowing scores (see Supplementary Figure 2B, available at
http://onlinelibrary.wiley.com/doi/10.1002/acr.22676/abstract)
at week 24 were markedly lower in patients receiving CZP
200 mg or CZP 400 mg compared with those receiving place-
bo (see Supplementary Figure 2).
Safety and tolerability. All safety data from the 2 trials
have previously been reported in detail (19,20). In all treat-
ment groups, the overall incidence of TEAEs appeared
to be higher with increasing baseline dose of MTX (see
Supplementary Table 1, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/
10.1002/acr.22676/abstract). Incidence rates of withdrawal
due to TEAEs were low across the treatment groups and
similar in all MTX dose categories (Supplementary Table 1,
available at http://onlinelibrary.wiley.com/doi/10.1002/acr.
22676/abstract) with the most common TEAEs leading to
withdrawal being infections (22 patients).
The most frequently reported infectious TEAEs were
urinary tract infections, nasopharyngitis, and upper respi-
ratory tract infections, with incidence rates of any infec-
tion slightly increased in patients in the higher MTX dose
category compared to those in the lower dose category
(Supplementary Table 1, available at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22676/abstract). The overall
incidence rate of serious infections was similar across
MTX categories, with the most frequently reported serious
infections being pneumonia, erysipelas, and disseminated
tuberculosis (Supplementary Table 1, available at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22676/abstract).
The most frequent noninfectious TEAEs by primary sys-
tem organ class, which occurred in $5% of patients in any
one treatment group and MTX dose category, were back
pain, rheumatoid arthritis, headache, pyrexia, rash, contu-
sion, and cough (Supplementary Table 1, available at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22676/abstract). In
all randomized treatment groups, the incidence rate of most
categories of TEAEs was higher in patients receiving MTX
$15 mg/week compared with those receiving ,15 mg/week
(Supplementary Table 1, available at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22676/abstract). In particular, GI
disorder events were reported less frequently in those receiv-
ing,15 mg/week MTX compared to$15 mg/week MTX (12
[4.9%], 76 [11.1%], and 41 [8.1%] versus 38 [18.5%], 76
[16.3%], and 93 [19.3%] in CZP 200 mg, CZP 400 mg, and
placebo groups, respectively). Noninfectious serious TEAEs
were relatively rare, with the most common events reported
being RA and cerebrovascular accident (Supplementary
Table 1, available at http://onlinelibrary.wiley.com/doi/10.
1002/acr.22676/abstract). The MTX 3-dose categorization
sensitivity analysis also reported increasing incidence rates
of most categories of TEAEs at higher MTX dose categories.
Malignancies, including nonmelanoma skin cancer,
affected 17 patients overall in the RAPID 1 and RAPID 2
studies (19,20). When analyzed by baseline MTX dose cat-
egory, malignancies were reported in 9 patients in the
MTX ,15 mg/week group and in 8 patients in the MTX
$15 mg/week group.
Nine patients died during treatment, the details of
which have been previously reported (19,20). Of these, 7
received MTX ,15 mg/week (all of which received MTX
#10 mg/week), and 2 received MTX $15 mg/week. In all
cases, events leading to death were judged as being unre-
lated to or unlikely to be related to study medication by
the investigator.
DISCUSSION
The results of this subgroup analysis demonstrate that CZP
reduces the signs and symptoms of RA and inhibits pro-
gression of joint damage with respect to placebo to a similar
extent regardless of the baseline dose category of MTX.
ACR20 response rates at week 24 in the CZP treatment
groups were unaffected by baseline MTX dose category
(MTX 2- and 3-dose categorizations). Regarding ACR50
and ACR70 response rates, there seemed to be a trend for
numerically slightly higher response rates in higher MTX
dose categories.
In the CZP 200 mg group, a slightly greater DAS28-ESR
mean change from baseline was observed with increasing
baseline MTX dose. This finding was primarily driven by
the lower changes from baseline DAS28-ESR observed in
patients receiving the lowest dose of MTX (#10 mg/
week). However, no such trend was observed for the pla-
cebo or CZP 400 mg groups.
A number of systematic reviews have evaluated the effi-
cacy and safety of MTX as monotherapy or as therapy with
other DMARDs in RA, but provide no insight into the
impact of different background MTX dose categories on the
efficacy and safety of anti-TNF regimens (4,22,23). Data
from open-label studies have demonstrated that addition of
an anti-TNF (etanercept or infliximab) to background MTX
therapy may allow MTX dose reduction or discontinuation
without detrimental effects on efficacy (24–26).
The type of analyses described in the current paper, in
which efficacy and safety have been assessed over a range
of baseline MTX dose categories, has also been performed
for infliximab and golimumab (27,28). In the Japanese
infliximab study, there was comparable efficacy of inflixi-
Figure 3. Mean change from baseline in the modified Sharp/van
der Heijde score (SHS) at week 24 by baseline methotrexate
(MTX) dose category (intent-to-treat population; MTX 2-dose
categorization). Interaction P value between MTX ,15 mg/week
and MTX $15 mg/week across treatment groups based on analy-
sis of covariance (ANCOVA). Individual group P values based
on ANCOVA. CZP5 certolizumab pegol.
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mab in RA patient subgroups receiving concomitant MTX
at low (#4 mg/week) or high ($6 mg/week) doses over 54
weeks (27). Despite the use of lower MTX doses in Japan
compared with those commonly utilized in the US and
Europe, these data are largely consistent with our current
findings in that the study drug was effective regardless of
MTX dosage. Similar findings were reported for golimu-
mab when the European League Against Rheumatism
response rate over 6 months was assessed by baseline
MTX dose category (,10 mg/week, $10 and ,15 mg/
week, or$15 mg/week) (28).
In a prospective early RA trial investigating the impact
of MTX dose category on the efficacy of adalimumab, simi-
lar results were reported for patients receiving MTX
10 mg/week and MTX 20 mg/week, but efficacy was lower
in patients receiving adalimumab in combination with
MTX 5 or 2.5 mg/week (29). Additionally, a trial investi-
gating MTX dose reduction in RA patients receiving adali-
mumab demonstrated similar outcomes for patients
receiving MTX 7.5 mg/week compared to those receiving
MTX 20 mg/week (30).
In our study, higher MTX doses seemed to be associated
with an increased incidence of TEAEs. This was observed
for infections and serious TEAEs, and was particularly
the case for GI TEAEs. These observations are consistent
with previous reports that describe MTX dose-dependent
increases in TEAEs in patients with RA (6,8,9,29,30). In an
analysis of the safety of adalimumab in combination with
different MTX doses in early RA, the incidence of infections
appeared to be MTX dose category dependent (30), although
the incidence rates of other TEAEs did not differ substan-
tially between doses. This finding should be interpreted
with caution, however, as MTX dose was not randomly
assigned in the present study, and patients on higher MTX
doses may be more prone to specific TEAEs due to more
active disease.
The mean baseline MTX dose was approximately
13.5 mg/week in RAPID 1 and approximately 12.5 mg/week
in RAPID 2 (19,20). These doses are low compared with cur-
rent clinical practice recommendations for the use of MTX
in RA, which suggest starting on MTX 10–15 mg/week and
then escalating by 5 mg every 2–4 weeks to 25–30 mg/week
or the highest tolerated dose, with a subsequent switch to
subcutaneous administration in the event of an inadequate
response (4,23). Although all enrolled patients were required
to have active RA despite at least 6 months of MTX therapy,
incomplete MTX response was at the discretion of the inves-
tigator, and therefore the MTX dose may have not been opti-
mized in enrolled patients receiving the lower doses of MTX
(#10 mg/week). Nevertheless the doses reflect those used in
local clinical practice at the time of study, and the results
from this analysis show similar efficacy for patients treated
with CZP regardless of baseline MTX dose category. Further-
more, it should be noted that approximately 40% of the
patients included in the pre-specified 2-dose analysis
received MTX doses of$15 mg/week at baseline.
This analysis has several limitations. First, it is a sub-
group analysis, and neither RAPID 1 nor RAPID 2 was
powered to detect clinically relevant MTX dose-related
differences among the treatment effects. Second, mandato-
ry withdrawal of ACR20 nonresponders at week 16 and
the 2:2:1 randomization ratio in the trials resulted in lon-
ger mean exposure to the study drug in the CZP groups
versus the placebo group (19,20). This limitation, how-
ever, was somewhat mitigated in the AE analysis by
reporting data as the number of cases per 100-patient
years. However, this method has limitations in itself, espe-
cially with low-incidence TEAEs. For GI disorders, we
therefore additionally reported the number of events and
percentage of patients affected. Third, patients receiving
the different baseline MTX doses may not have been simi-
lar in terms of the underlying disease process; physicians
often prescribe higher MTX doses to better control the dis-
ease process, resulting in patients with poorer disease
control receiving higher MTX doses. However, the base-
line disease activity was similar across all dose categories,
which may suggest that differences in dose reflect differ-
ences in local practice in the countries in which the stud-
ies were conducted. It is also not known whether patients’
baseline MTX dose represented the optimum dose to con-
trol their disease. Furthermore, no change or tailoring of
the MTX dose was permitted during the study so it is not
known whether a change in the MTX dose would lead to a
difference in efficacy. Finally, these analyses were con-
ducted in a clinical trial setting in patients with high dis-
ease activity at baseline, from a wide range of geographies,
and who had already tolerated at MTX doses of at least
10 mg/week for over 6 months. These factors need to be
considered when generalizing the results to patients in
clinical practice, particularly those who are unable to tol-
erate even low doses of MTX.
In conclusion, this subgroup analysis suggests that CZP
in combination with MTX reduces the signs and symp-
toms of RA and inhibits radiographic progression com-
pared with placebo, irrespective of the baseline MTX dose
category. Higher-dose MTX was associated with an
increase in the incidence of most TEAEs across all treat-
ment groups, but TEAEs were generally mild to moderate.
There was also a trend for numerically higher ACR50 and
ACR70 rates in higher-dose MTX patients. However, the
fact that the efficacy of CZP remains high across a range of
baseline MTX dose categories may offer a particular bene-
fit to patients who are unable to tolerate high doses of
MTX, hypothetically allowing physicians to tailor the
MTX dose to the individual patient’s tolerance without
significantly compromising the efficacy of CZP.
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